We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 1

Figure 1. From: Osteoblastogenesis and tumor growth in myeloma.

Interactions of myeloma cells with osteoblasts and their precursors. Soluble factors (e.g. DKK1) and dysregulated cell-surface molecules (e.g. ephrinB2/EphB4) are involved in MM-induced suppression of osteoblastogenesis and subsequent stimulation of osteoclastogenesis. Osteoblast precursors and osteoclasts provide sanctuary to and stimulate growth of myeloma cells through cell–cell contact interactions and production of growth factors. Osteoblast-activating agents (e.g. bortezomib, anti-DKK1) increase the number of bone-building osteoblasts, resulting in normalization of osteoclastogenesis through increased production of anti-osteoclastogenic factors (e.g. OPG). Bone-building osteoblasts attenuate myeloma cell growth by increasing levels of potential anti-myeloma and anti-angiogenic factors (e.g. certain SLRPs) in the MM bone marrow microenvironment.

SHMUEL YACCOBY. Leuk Lymphoma. ;51(2):213-220.

Supplemental Content

Filter your results:

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk